We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

85 hedge funds and large institutions have $426M invested in Adaptimmune Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more call options, than puts

Call options by funds: $725K | Put options by funds: $429K

0.19% more ownership

Funds ownership: 11.92% → 12.12% (+0.19%)

8% less funds holding

Funds holding: 92 → 85 (-7)

26% less capital invested

Capital invested by funds: $577M → $426M (-$151M)

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

48% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 33

Holders
85
Holders Change
-7
Holders Change %
-7.61%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
17
Reduced
33
Closed
21
Calls
$725K
Puts
$429K
Net Calls
+$296K
Net Calls Change
-$235K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$8.69M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$4.24M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.23M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.95M
5
DCM
DAFNA Capital Management
California
+$620K

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$5.47M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.3M
3
Marshall Wace
Marshall Wace
United Kingdom
-$4.49M
4
GCP
GSA Capital Partners
United Kingdom
-$1.82M
5
SSA
Schonfeld Strategic Advisors
New York
-$1.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
51
XTX Topco
Cayman Islands
$66K +$79.9K +17,560 New
UBS Group
52
UBS Group
Switzerland
$61K +$4.86K +1,067 +7%
Tudor Investment Corp
53
Tudor Investment Corp
Connecticut
$60K -$464 -102 -0.6%
IA
54
Inspire Advisors
Idaho
$58K +$70.1K +15,393 New
HighTower Advisors
55
HighTower Advisors
Illinois
$53K – – –
IUHSA
56
Itau Unibanco Holding S.A.
Brazil
$51K -$1.12K -246 -2%
AIM
57
Aigen Investment Management
New York
$43K +$53.6K +11,776 New
HAIM
58
Hunter Associates Investment Management
Pennsylvania
$41K +$50.1K +11,000 New
CPIG
59
Chicago Partners Investment Group
Illinois
$38K +$55.8K +12,265 New
Simplex Trading
60
Simplex Trading
Illinois
$35K -$17.7K -3,882 -29%
CG
61
Cutler Group
California
$31K +$33.2K +7,300 +608%
VRM
62
Vectors Research Management
New York
$26K +$4.55K +1,000 +17%
FIA
63
FNY Investment Advisers
New York
$22K -$29.6K -6,500 -52%
TRCT
64
Tower Research Capital (TRC)
New York
$22K -$14.3K -3,151 -35%
Wells Fargo
65
Wells Fargo
California
$20K – – –
US Bancorp
66
US Bancorp
Minnesota
$17K -$5.83K -1,280 -22%
S
67
SignatureFD
Georgia
$16K +$105 +23 +0.5%
EBA
68
Eagle Bay Advisors
New York
$15K -$2.24K -492 -13%
LC
69
Lindbrook Capital
California
$12K -$24.5K -5,392 -62%
HWA
70
Heritage Wealth Advisors
Virginia
$12K – – –
QCG
71
Quadrant Capital Group
Ohio
$9K -$3.43K -754 -23%
Rockefeller Capital Management
72
Rockefeller Capital Management
New York
$7K – – –
Osaic Holdings
73
Osaic Holdings
Arizona
$5K +$910 +200 +19%
BBPWM
74
Blue Bell Private Wealth Management
Pennsylvania
$5K +$6.19K +1,359 New
CAPTRUST Financial Advisors
75
CAPTRUST Financial Advisors
North Carolina
$4K – – –
1 2
3
4 5

ADAP Hedge Fund Activity: Q4 2021 in Review

85 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2021, worth a combined $426M — down 26% from $577M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ADAP and 15 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 17 added.

The largest buyer was Morgan Stanley, adding an estimated $8.69M. The largest seller was PFM Health Sciences, cutting an estimated $5.47M.

  • 85 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2021, down from 92 in Q3 2021.
  • Funds reported $426M of Adaptimmune Therapeutics stock for Q4 2021, down 26% quarter-over-quarter.
  • 15 funds opened new Adaptimmune Therapeutics positions in Q4 2021 and 21 closed out, a net change of -6 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $8.69M added.
  • The largest Adaptimmune Therapeutics seller in Q4 2021 was PFM Health Sciences, an estimated $5.47M sold.

Based on aggregated 13F filings for Q4 2021.